Initial efforts focused on extrapolating established biomarkers from non-small cell lung cancer (NSCLC), such as PD-L1 expression and tumor mutational burden (TMB).9 Paradoxically, in SCLC, the value of these markers for immunotherapy responsiveness remains controversial. The gene discussed is CD274; the disease is non-small cell lung carcinoma.